BrainsWay (BWAY) Q4 2025 earnings review
Operating Leverage Kicks In as Lease Strategy Accelerates
BrainsWay delivered an exceptional quarter, growing revenue 27% YoY to a record $14.5 million while blowing past profitability milestones. The company's strategic shift toward multi-year lease agreements with enterprise mental health networks is paying off rapidly, expanding Remaining Performance Obligations (RPO) by 43% YoY to $70 million. Most impressively, the top-line growth is flowing straight to the bottom line—Adjusted EBITDA grew 53% in Q4, and full-year net income surged 161%. With 2026 guidance pointing to an acceleration in EBITDA growth (86%-100% YoY), BrainsWay is successfully transitioning from an early-stage med-tech hardware vendor to a highly profitable, recurring-revenue platform.
🐂 Bull Case
Approximately 70% of new engagements are multi-year leases. This model has driven RPO to $70 million, providing exceptional visibility into future cash flows and lowering the barrier to entry for clinic partners.
The company's scale is translating directly into margins. Operating income guided for 13-14% in 2026 implies massive operating leverage, allowing the company to self-fund strategic acquisitions and clinical trials.
🐻 Bear Case
Despite a massive shift toward software-like leasing models, gross margins remained flat at 75% for the full year. Further profitability will have to come entirely from OPEX leverage rather than unit economics.
While operating cash flow was strong at $18 million for 2025, cash and equivalents actually shrank YoY due to heavy investments ($14.5M) in minority clinic stakes. This strategy carries high execution and impairment risk.
⚖️ Verdict: 🟢🟢
Bullish. Management is executing flawlessly on its dual mandate of top-line growth and margin expansion. The 2026 guidance for 86-100% EBITDA growth confirms that the inflection point achieved in 2025 is structural, not a one-off.
Key Themes
Lease-Based Enterprise Model Maximizing Visibility
BrainsWay has firmly established its transition to a recurring revenue framework, noting that ~70% of customer engagements signed recently are multi-year lease agreements. This shift drove a massive 43% YoY increase in Remaining Performance Obligations (RPO) to $70 million. This structural change stabilizes cash flow and drives high customer retention across large mental health networks.
Clinical and Regulatory Moat Widening
The FDA granted multiple critical label expansions, significantly widening the total addressable market. Most notably, the SWIFT protocol received its first insurer coverage, dramatically shortening treatment time from weeks to days. Additionally, the FDA cleared Deep TMS for adolescents (15-21) with MDD, giving BrainsWay unique access to a demographic severely impacted by the ongoing mental health crisis.
Strategic Minority Investments Fueling Growth
BrainsWay is leveraging its strong balance sheet to aggressively purchase minority equity stakes in leading mental health networks (e.g., Stella MSO, Axis). This vertical integration tactic guarantees BrainsWay a captive customer base for system placements and effectively locks out competing TMS manufacturers in those clinics.
Gross Margins Are Flat Contradicting the 'Lease' Narrative
A specific contradiction emerged in the numbers: despite the rapid mix shift toward multi-year lease agreements—which typically command higher lifetime value and margins than one-off equipment sales—full-year gross margins remained entirely stable at 75%. If the leasing model is vastly superior, it is currently being offset by higher hardware costs, inflation, or aggressive pricing to win enterprise network deals.
Macro: Tariff Vulnerabilities on Israeli Exports
Given BrainsWay's manufacturing footprint, the company remains exposed to geopolitical trade risks. Prior quarters noted potential vulnerability to the U.S. administration's proposed 17% reciprocal tariff plan on Israeli imports. While demand currently outstrips this headwind, a heavy tariff could force BrainsWay to either absorb margin hits or pass costs to clinics, potentially slowing system adoption.
Heavy Cash Drain for Minority Stakes
While operating cash flow was stellar ($18.0 million for FY25), BrainsWay essentially spent all of it on investing activities ($17.5 million outlaid), explicitly driven by $14.5 million used to purchase financial assets (minority clinic stakes). Cash on hand slightly decreased from $69.3M to $67.7M as a result. While strategic, this converts liquid cash into illiquid, risky private equity bets.
Other KPIs
Accelerating. Total installed base reached approximately 1,700 systems globally, bolstered by a record 95 net Deep TMS systems shipped in Q4 alone—a 27% increase YoY.
Accelerating sharply compared to $10.3 million in FY24. The 75% increase in operational cash generation confirms that the reported net income is backed by genuine cash collection, pointing to excellent working capital management despite the shift toward leasing.
Guidance
Accelerating nominally. The midpoint ($67.0M) represents 28.5% YoY growth, slightly higher than the 27% growth achieved in FY25. This proves management expects the combination of new indications (Adolescent MDD) and network expansions to easily sustain the current momentum.
Accelerating aggressively. The midpoint ($13.0M) implies an 86% YoY jump compared to the $7.0 million delivered in FY25. This underscores massive operating leverage as the SG&A infrastructure built in 2024/2025 begins to yield outsized returns on incremental lease revenue.
Accelerating. Compares favorably to the 8.2% operating margin achieved in FY25. Indicates strong forward confidence in scaling expenses effectively without sacrificing top-line momentum.
Key Questions
Gross Margin Stagnation
With 70% of new engagements transitioning to multi-year leases, why did full-year gross margins remain flat at 75%? Are there elevated hardware production costs or pricing concessions offsetting the margin mix benefit?
Minority Investment Returns
You deployed $14.5 million into financial assets (minority stakes) this year. What specific ROI metrics or system-placement quotas are attached to these investments to ensure they generate shareholder value rather than just masking customer acquisition costs?
Tariff Mitigation Strategy
Should the proposed 17% U.S. reciprocal tariff on Israeli imports take effect, how much of that cost can be passed through to your enterprise network partners versus absorbed into your 2026 operating margin guidance?